CN1301121C - Medicine for curing toxuria - Google Patents

Medicine for curing toxuria Download PDF

Info

Publication number
CN1301121C
CN1301121C CNB031114970A CN03111497A CN1301121C CN 1301121 C CN1301121 C CN 1301121C CN B031114970 A CNB031114970 A CN B031114970A CN 03111497 A CN03111497 A CN 03111497A CN 1301121 C CN1301121 C CN 1301121C
Authority
CN
China
Prior art keywords
medicine
parts
radix
taken
obvious
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB031114970A
Other languages
Chinese (zh)
Other versions
CN1456195A (en
Inventor
朱白
黄树明
黄丽
刘砺力
李光伟
Original Assignee
JILIN CITY CENTER HOSPITAL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by JILIN CITY CENTER HOSPITAL filed Critical JILIN CITY CENTER HOSPITAL
Priority to CNB031114970A priority Critical patent/CN1301121C/en
Publication of CN1456195A publication Critical patent/CN1456195A/en
Application granted granted Critical
Publication of CN1301121C publication Critical patent/CN1301121C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention relates to medicine for treating uraemia, which is prepared from the following raw material by weight proportions: 2 to 4 parts of ginseng, 20 to 50 parts of membranous milkvetch root, 10 to 20 parts of prepared rehmannia root, 5 to 15 parts of barbary wolfberry fruit, 3 to 10 parts of cassia bark, 2 to 15 parts of angelica, 3 to 10 parts of mirabilite, 30 to 60 parts of motherwort herb, 5 to 10 parts of twotooth achyranthes root and 1 to 2 parts of rhubarb. The medicine which is a granule preparation has the functions of spleen invigorating, qi replenishing, kidney warming, spleen strengthening, blood circulation activation, blood stasis dissipation, catharsis, toxin expulsion, toxic nitrogen reduction in hematuria, muscle and liver balancing, chronic renal failure control. The medicine is taken for 15 grams each time and for 2 times a day; the medicine is taken accompanied with warmed water on an empty stomach, and average time for taking the medicine is 3 months. Clinical observation shows that an effective rate is 84.7%; after the medicine is taken for 1 month, obvious effects are shown, namely that P is less than 0.05; however, after patients in a contrast group take Shenan medicine for 2 months, differences are still not obvious, namely that P is more than 0.05. The medicine for treating uraemia in the present invention has obvious curative effects on the reversion and the stabilization of illness states and the control of uremia progression, and has no toxic side effects.

Description

Treat uremic medicine
Technical field
The invention belongs to the field of Chinese medicines, relate to and a kind ofly reduce that hematuria poison nitrogen, flesh edema caused by disorder of the liver are flat, the uremic electuary of treatment of postponing chronic kidney function failure.
Background technology
Uremia is the common frdquently encountered disease of serious threat human body health, or even child how old also has this disease of suffering from.This disease is a kind of difficult disease, and the ill later stage need be carried out hemodialysis and be earned a bare living, and the required expense costliness of at every turn dialysing is that common people are difficult to bear.Take kidney peace weak curative effect in the former Therapeutic Method, side effect is big.
Summary of the invention
The objective of the invention is to overcome the deficiency that prior art exists, a kind of invigorating the spleen and replenishing QI that has is provided, warming the kidney and strengthening the spleen, blood circulation and removing stasis, purging FU-organs rush down turbid function, treatment uremia, hematuria poison nitrogen, flesh edema caused by disorder of the liver are flat to reduce, the curative effect of postponing chronic kidney function failure electuary preferably.
The objective of the invention is to be achieved by following technical proposals:
The uremic medicine of a kind of treatment is characterized in that it is to be made by following materials of weight proportions:
Radix Ginseng 2~4 Radixs Astragali 20~50 Radix Rehmanniae Preparata 10~20 Fructus Lycii 5~15
Cortex Cinnamomi 3~10 Radix Angelicae Sinensis 2~15 Natrii Sulfas 3~10 Herba Leonuris 30~60
Radix Achyranthis Bidentatae 5~10 Radix Et Rhizoma Rhei 1~2
The dosage form of aforesaid medicine is a dissolved granule.
Technical scheme of the present invention is based on motherland's medical science to uremic understanding and Therapeutic Principle, draw the elite in the research for many years, therefrom filter out suitable natural vegetable Chinese herbal medicine, prescription is scientific and reasonable, reuse Radix Ginseng, the Radix Astragali, Radix Rehmanniae Preparata in the side, invigorating QI to consolidate the body surface resistance, poison holding life, warming and recuperating the spleen and kidney; The minister Radix Angelicae Sinensis, the strengthening the spleen blood circulation and removing stasis is mended tissue regeneration promoting blood; Assistant Fructus Lycii, Cortex Cinnamomi nourishing the kidney and liver, enhancing immunity, warming and recuperating the kidney-YANG makes Radix Achyranthis Bidentatae the kidney invigorating priming descending, controls dysuria; Radix Et Rhizoma Rhei, Natrii Sulfas can rush down turbid by purging FU-organs.The said medicine compatibility rationally can improve tonifying speen and tonifying kidney, warming the kidney to invigorate YANG, and blood circulation and removing stasis, purging FU-organs rush down turbid function.
The uremic medicine of treatment provided by the invention-uremic health, through the preuremic stage patient clinical observation, have significant curative effect than the treatment of present technology kidney peace, obvious reverse is arranged, stablize the state of an illness, delay disease and make progress, and find no toxic and side effects.On average taking medicine 3 months, is 84.7% through the clinical observation obvious effective rate, medication 1 month, just there were significant differences P<0.05; And kidney peace matched group was taken medicine the still not obvious P of difference>0.05 2 months.
Function with cure mainly: invigorating the spleen and replenishing QI, warming the kidney and strengthening the spleen, blood circulation and removing stasis, purging FU-organs rush down turbid.Be applicable to uremia, can reduce hematuria poison nitrogen, the flesh edema caused by disorder of the liver is flat, the depletion of delaying chronic kidney merit.
Usage and consumption: oral 15g/ time, 1 twice-daily, early, late (medicine) being taken before meal uses.
Above-mentioned treatment uremia, as experimental group, taking the kidney peace with 60 examples by former Therapeutic Method is matched group, respectively through clinical observation through 180 routine uremic patients.1 month is 1 course of treatment, average medication 3 months, and clinical symptoms, Signs and lab testing obviously improve, and total effective rate is 84.7%.With kidney peace group curative effect comparision symptom, Signs is partly used X 2Check, laboratory data-check just had significant difference P value<0.05 in 1 month after the experimental group medication; And treatment of control group after 2 months difference remarkable P value>0.05 still.The uremic medicine of treatment of the present invention has the tangible reverse and the stable state of an illness, delays the curative effect of uremia's progress, does not find toxic side effect.
The specific embodiment
Now in conjunction with the embodiments technical scheme of the present invention is further described.
Embodiment
1. take by weighing the raw material (kg) that each embodiment needs by following proportioning
Radix Ginseng The Radix Astragali Radix Rehmanniae Preparata Fructus Lycii Cortex Cinnamomi Radix Angelicae Sinensis Natrii Sulfas Herba Leonuri Radix Achyranthis Bidentatae Radix Et Rhizoma Rhei
Embodiment 1 2 20 10 5 3 2 3 30 5 1
Embodiment 2 3 35 15 10 6.5 8.5 6.5 45 7.5 1.5
Embodiment 3 4 50 20 15 10 15 10 60 10 2
2, production method
(1) with the above-mentioned Radix Astragali, Radix Rehmanniae Preparata, Herba Leonuri and Radix Achyranthis Bidentatae four flavor raw materials, select clean, remove impurity after, take by weighing by embodiment 1~3 needed raw material in the above-mentioned table, adding its consumption of water is 3 times of material quantities, decocts each 3 hours 3 times, three times filtrate is mixed through being condensed into the thick paste shape, add 3 times of amount ethanol, static 48 hours, filtrate recycling ethanol gets its extractum, and is standby;
(2) remaining six kinds of raw material Radix Ginsengs, Radix Angelicae Sinensis, Fructus Lycii, Cortex Cinnamomi, Radix Et Rhizoma Rhei and Natrii Sulfas are selected, Ex-all impurity with ordinary water flush away earth, after 50~70 ℃ of oven dry, mixes and pulverizes (slowly pulverizing) to 100 order fineness;
(3) system soft material: extractum and raw material medicated powder, xylitol, starch are made soft material after mixing;
(4) granulate: the above-mentioned soft material that makes through granulating and crossing 10 mesh sieves, is drying to obtain in 50 ℃ of hothouses;
(5) granulate: an above-mentioned dry back material is sieved, get by No. 4 sieves, and can not be by whole granule mixings of No. 1 sieve, sampling inspection;
(6) packing: through chemically examining qualified granule, in aseptic subpackaged indoor packing, press the loading amount pack of 15g/ bag, and press the loading amount dress box (or by 12 pouches/sack loading amount pack) of 15g * 12 bag/box, vanning is put in storage then.
The uremic medicament selection of the above-mentioned treatment that makes is an electuary.Powder is difficult to make in the raw material effective ingredient more to give full play to drug effect, takes the decocting and concentrating extraction method, can give full play to its drug effect, to reach best therapeutic effect.Above-mentioned electuary outward appearance is sepia or yellowish-brown, sweet and slightly bitter taste.Add xylitol during the system soft material, make to be applicable to simultaneously that also suffering from diabetics takes by the uremic uremic health of treatment provided by the invention medicine.

Claims (2)

1, the uremic medicine of a kind of treatment is characterized in that it is to be made by following materials of weight proportions
Radix Ginseng 2~4 Radixs Astragali 20~50 Radix Rehmanniae Preparata 10~20 Fructus Lycii 5~15
Cortex Cinnamomi 3~10 Radix Angelicae Sinensis 2~15 Natrii Sulfas 3~10 Herba Leonuris 30~60
Radix Achyranthis Bidentatae 5~10 Radix Et Rhizoma Rhei 1~2.
2, medicine according to claim 1, the dosage form that it is characterized in that described medicine is a dissolved granule.
CNB031114970A 2003-04-16 2003-04-16 Medicine for curing toxuria Expired - Fee Related CN1301121C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB031114970A CN1301121C (en) 2003-04-16 2003-04-16 Medicine for curing toxuria

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB031114970A CN1301121C (en) 2003-04-16 2003-04-16 Medicine for curing toxuria

Publications (2)

Publication Number Publication Date
CN1456195A CN1456195A (en) 2003-11-19
CN1301121C true CN1301121C (en) 2007-02-21

Family

ID=29411226

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB031114970A Expired - Fee Related CN1301121C (en) 2003-04-16 2003-04-16 Medicine for curing toxuria

Country Status (1)

Country Link
CN (1) CN1301121C (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102028897B (en) * 2010-12-08 2012-02-15 山西医科大学第一医院 Chinese patent drug for treating glomerular hematuria and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1192928A (en) * 1997-03-11 1998-09-16 凉城县鸿茅酒厂 Production process for medicinal liquor
CN1334118A (en) * 2001-08-09 2002-02-06 刘广斌 Chinese medicine for treating uremia
CN1398621A (en) * 2002-09-10 2003-02-26 袁东林 Kidney-invigorating capsule and its prepn

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1192928A (en) * 1997-03-11 1998-09-16 凉城县鸿茅酒厂 Production process for medicinal liquor
CN1334118A (en) * 2001-08-09 2002-02-06 刘广斌 Chinese medicine for treating uremia
CN1398621A (en) * 2002-09-10 2003-02-26 袁东林 Kidney-invigorating capsule and its prepn

Also Published As

Publication number Publication date
CN1456195A (en) 2003-11-19

Similar Documents

Publication Publication Date Title
CN1194843A (en) Method for producing green health medicine
CN102370949A (en) Chinese medicinal compound preparation for treating cholecystitis and preparation method thereof
CN100342891C (en) Medicine composition for hypertension and its preparation thereof
CN1682982A (en) Yishenkangshuai pill for treating chronic nephrosis and renal failure
CN1814208A (en) Oral Chinese medicine for treating and preventing recurrence of uecerative stomatitis
CN1486740A (en) Chinese medicine composition for treating cancer
CN102302609A (en) Compound traditional Chinese drug preparation for improving subhealth
CN102657736B (en) Medicament composition for treating rheumatoid arthritis and preparation method of medicament composition
CN1289114C (en) Arthralgia pain treating bolus and its prepn
CN1301121C (en) Medicine for curing toxuria
CN1097621A (en) Anti-cancer powder
CN1305816A (en) Medicine for treating diabetes
CN1051471C (en) Drug composition for curing osteoporosis
CN1440804A (en) Antilipemic Chinese medicine
CN1242775C (en) Bushenshansong drink and preparation method thereof
CN1695639A (en) Chinese traditional medicine for treating dysmenorrhea and irregular menses, and preparation method
CN1314160A (en) Oral pill for curing diabetes and its complication
CN1340353A (en) Orally-applied medicine for treating hepatism and its preparing process
CN1813876A (en) Xian Pengliaofu oral preparation-a Chinese medicine for treating bone disease
CN1192913A (en) Shentong capsule and preparing method thereof
CN1068217C (en) Traditional Chinese medicine for treating skin disease and veneral disease
CN1319583C (en) Medicine for treating lung cancer and preparing process thereof
CN1660211A (en) Combination of medication for treating gallbladder disease and preparation method
CN1060677C (en) Preparation for senile disease
CN100333780C (en) Chinese medicine for antisenility and its preparation method

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: ZHU BAI

Free format text: FORMER OWNER: JILIN CENTER HOSPITAL

Effective date: 20070608

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20070608

Address after: 132001 No. 4, Nanjing street, Jilin, Jilin

Patentee after: Zhu Bai

Address before: 132001 No. 4, Nanjing street, Jilin, Jilin

Patentee before: Jilin City Center Hospital

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070221

Termination date: 20130416